Last reviewed · How we verify
NCT05696184
Mechanisms Preventing Pharyngeal Reflux
NA trial testing Concurrent manometry/impedance/pH with video pharyngo-laryngoscopy in GERD in 300 participants. Currently enrolling.
12 October 2026
Quick facts
| Lead sponsor | Medical College of Wisconsin |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 300 |
| Start date | 1 November 2013 |
| Primary completion | 12 October 2026 |
| Estimated completion | 12 October 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Concurrent manometry/impedance/pH with video pharyngo-laryngoscopy
- Slow and rapid intra-esophageal infusion
Conditions studied
- GERD — all drugs for GERD →
Sponsor
Medical College of Wisconsin
Who can join
Adults 18 to 85, any sex, with GERD. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The overall goal is to define and characterize the manometric characteristics of UES incompetence associated with objectively documented pharyngeal reflux. The investigators will use endoscopic reflux detection as gold standard.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05696184
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for GERD
Currently open trials in the same condition.
- NCT06953986 — A Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA · NA · recruiting
- NCT07421011 — Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 · Phase 1 · recruiting
- NCT07268820 — Heartburn, Gastroesophageal Reflux Disease · Phase 4 · recruiting
- NCT06955520 — Vonaprazan Versus Esomeprazole for Healing of LA Grade B or Higher Esophagitis After POEM · NA · recruiting
- NCT06641375 — Anti-Reflux Endoscopic Therapy Using Argon Plasma Coagulation (AREA) in Gastroesophageal Reflux Disease (GERD) Patients: · NA · recruiting
Other Medical College of Wisconsin trials
Trials by the same sponsor.
- NCT07260552 — Rapid Engagement for Solutions to Population and Outcomes Through Networked Dialogue for Coronary Heart Disease · not yet recruiting
- NCT06795360 — Weight Changes After Incretin-mimetics · NA · not yet recruiting
- NCT07228208 — Role of Endothelial Dysfunction on Exercise Pressor Reflex in Type 2 Diabetes · NA · not yet recruiting
- NCT07298460 — Stimulation-based Therapy to Improve Balance in DCM · Phase 1, PHASE2 · not yet recruiting
- NCT07434544 — Cardiometabolic Effects of Non-Nutritive Sweeteners (NNS) in Type 1 Diabetes (T1D) · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05696184 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medical College of Wisconsin
- Last refreshed: 10 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05696184.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing